No Survival Benefit from the Inhibition of Renin-Angiotensin System in Biliary Tract Cancer

• Published in: Anticancer research 2016-09, Vol.36 (9), p.4965-4970
• Main Authors: Nakai, Yousuke, Isayama, Hiroyuki, Sasaki, Takashi, Takahara, Naminatsu, Saito, Kei, Takeda, Tsuyoshi, Umefune, Gyotane, Saito, Tomotaka, Takagi, Kaoru, Watanabe, Takeo, Hamada, Tsuyoshi, Uchino, Rie, Mizuno, Suguru, Yamamoto, Keisuke, Kogure, Hirofumi, Matsubara, Saburo, Yamamoto, Natsuyo, Ijichi, Hideaki, Tateishi, Keisuke, Tada, Minoru, Koike, Kazuhiko
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors - administration & dosage; Biliary Tract Neoplasms - drug therapy; Biliary Tract Neoplasms - pathology; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Renin-Angiotensin System - drug effects; Treatment Outcome
• ISSN: 0250-7005; 1791-7530
• DOI: 10.21873/anticanres.11065

The renin-angiotensin system (RAS) was investigated as a target for cancer treatment. A total of 287 patients with biliary tract cancer (BTC) receiving chemotherapy were retrospectively studied to evaluate the role of inhibition of RAS by angiotensin system inhibitors (ASIs). Progression-free survival (PFS) and overall survival (OS) were compared between 74 patients with hypertension, on ASIs (ASI group), 50 patients with hypertension not on ASIs (non-ASI with HT group) and 163 patients without hypertension (non-HT group). Interactions between the use of ASIs and various subgroups were explored. The median PFS was 3.6, 3.9 and 4.6 months (p=0.495) and the median OS was 11.6, 10.9 and 13.1 months (p=0.668), respectively. The use of ASIs was not associated with OS (hazard ratio 1.00, p=0.975) and no subgroups with better survival were identified. No survival benefit from ASIs was observed in BTC.